320 related articles for article (PubMed ID: 28276288)
1. Golimumab for moderate to severe ulcerative colitis.
Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
[TBL] [Abstract][Full Text] [Related]
2. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
Berends SE; Strik AS; Jansen JM; de Boer NK; van Egmond PS; Brandse JF; Mathôt RA; D'Haens GR; Löwenberg M
Scand J Gastroenterol; 2019 Jun; 54(6):700-706. PubMed ID: 31132014
[No Abstract] [Full Text] [Related]
4. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
[TBL] [Abstract][Full Text] [Related]
5. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
[TBL] [Abstract][Full Text] [Related]
6. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
[TBL] [Abstract][Full Text] [Related]
7. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
Vande Casteele N; Khanna R
Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
[TBL] [Abstract][Full Text] [Related]
9. UK guidance opens new therapeutic avenues for patients with moderate-severe ulcerative colitis.
Orchard T
Expert Rev Gastroenterol Hepatol; 2016; 10(3):281-2. PubMed ID: 26651595
[No Abstract] [Full Text] [Related]
10. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
[TBL] [Abstract][Full Text] [Related]
13. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
16. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
19. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]